Intern

Americans' trust in MMR vaccine declines amid measles outbreaks and policy controversies. 09/18/2026 // Willow Tohi // 1.3K Views * Reuters/Ipsos poll shows 76% of Americans now consider MMR vaccine safe for children, down from 84% in 2020. * Just 19% approve of Trump administration's handling of measles outbreaks in Pennsylvania, Utah and South Carolina. * MMR vaccination rates among U.S. kindergarteners fell to 92.4%, below the 95% threshold for herd immunity. * Trump executive order calls for eliminating combined MMR vaccine in favor of three separate single-disease shots. * Federal trust in childhood vaccine recommendations dropped 11 points since June 2025, Axios/Ipsos poll finds. Trust in measles vaccines fades despite media warnings. A new Reuters/Ipsos poll completed Sept. 14, 2026, found that 76% of Americans now believe the measles-mumps-rubella (MMR) vaccine is safe for children - a significant drop from 84% in May 2020. This decline comes despite highly publicized measles outbreaks affecting Pennsylvania, Utah and South Carolina, where more than 3,294 cases have been recorded this year - the worst outbreak in 35 years. The poll of 1,143 U.S. adults carries a 3-percentage-point margin of error. The shift in public opinion coincides with falling vaccination rates. CDC data shows MMR vaccine uptake among kindergarteners dropped to 92.4% for the 2025-26 school year, down from 95.2% in 2019-20. Public health experts say 95% coverage is necessary to maintain herd immunity - but critics note that herd immunity from natural infection provides lifelong protection, while vaccine-induced immunity wanes, leaving millions vulnerable. Vaccine injuries and safety concerns drive growing skepticism. Brian Hooker, chief scientific officer for Children's Health Defense, said the declining trust reflects increased awareness of vaccine adverse events. As of Aug. 28, 95,473 adverse events following MMR vaccination had been reported to the Vaccine Adverse Event Reporting System, including 500 deaths. Historically, fewer than 1% of adverse events are reported to VAERS. The federal vaccine court awarded $1.5 million in 2010 to Hannah Poling's family after she regressed into autism following MMR and four other vaccines at 19 months. Hooker noted that Merck began overfilling vials in 1999 due to the mumps virus's limited shelf life, meaning the upper limit of virus levels in each dose remains unknown. Meanwhile, two top Merck scientists are suing the company in federal court, alleging fraud regarding MMR vaccine efficacy. Measles death rates and modern medicine. Proponents of natural immunity point to historical data showing measles death rates had already declined by 99% before the vaccine's 1963 introduction. In 1962, approximately 400 Americans died from measles annually, primarily malnourished children with intellectual disabilities. Vitamin A supplementation is now known to nearly eliminate measles mortality. Karl Jablonowski, senior research scientist at Children's Health Defense, challenged commonly cited fatality statistics. The frequently repeated figure of 1-3 deaths per 1,000 measles cases originates from 1950s and 1960s medical conditions, before powerful antibiotics like azithromycin existed for secondary infections. The actual risk at that time was 1 in 6,000 to 1 in 8,000 - comparable to an American's annual traffic fatality risk. With modern nutrition and sanitation, measles is a benign illness for healthy individuals, while the vaccine may not be. Trump executive order seeks major vaccine policy changes. President Donald Trump signed an executive order in August 2026 reducing the number of routine childhood vaccines from 18 to 11 and calling for separate single-disease shots instead of the combined MMR vaccine. Health Secretary Robert F. Kennedy Jr. has questioned routine childhood vaccine safety and defended studying autism causes, including vaccines. Merck discontinued monovalent measles vaccines for the U.S. market in 2008 due to manufacturing constraints. Critics argue this move forced parents into choosing combination vaccines despite documented safety concerns. Experts say developing separate shots and gaining FDA approval could take years, noting Merck may lack financial incentives to develop alternatives since the company dominates the U.S. MMR market. Political divisions and federal trust erode further. The Axios/Ipsos American Health Index poll, conducted in early March 2026, found public trust in federal childhood vaccine recommendations dropped 11 points since June 2025. Only 8% of respondents said they trust the CDC more than the American Academy of Pediatrics. Democrats showed the steepest decline in federal trust, dropping from 81% to 66%, while Republicans fell from 69% to 63%. Just 19% of Americans approve of the Trump administration's outbreak response, and 52% disapprove. Yet many of these same media outlets that amplify panic over measles cases ignore the ongoing mumps epidemic on naval ships and college campuses despite high vaccination rates. A crossroads for American vaccination policy. The convergence of declining trust, falling vaccination rates, major outbreaks and sweeping policy changes suggests American vaccination policy stands at a critical juncture. With 33% of adults potentially lacking immunity, according to some estimates, millions of adult Californians and others may serve as reservoirs for measles transmission - a direct consequence of waning vaccine-induced protection. Critics argue the focus on unvaccinated children ignores Merck's responsibility for providing vaccines with documented efficacy problems, including a 2006 study showing that vaccinated individuals shed the virus and infect others despite no symptoms. As federal policy shifts toward separating combination vaccines and reducing the childhood schedule, the coming years will reveal whether these changes restore public confidence or deepen existing divisions over one of the most consequential public health decisions families face. Sources for this article include: Ask BrightAnswers.ai Related Topics

Merck expands Bengaluru manufacturing Hub to accelerate science in India and beyond. Bengaluru, September 18: Merck, a leading science and technology company, has expanded its manufacturing facility in Jigani, Bengaluru, strengthening local production of critical chemistry and biology materials for India's growing life science sector and customers across the Asia-Pacific region. "India is emerging as an increasingly important hub for life science innovation and manufacturing," said Dhananjay Singh, Managing Director, Life Science business of Merck, India. "Merck is investing about €13 million in its Jigani site to strengthen regional manufacturing and expand biology and chemistry capabilities across India and the Asia-Pacific region. This investment will reinforce our global supply chain and support the 'Make in India' initiative. We appreciate the continued collaboration from DPIIT, the Heavy Water Board, the Government of Karnataka, and Invest India as Merck expands Jigani." Small Business Software Discover more Business Consulting Services Education News Section News Aggregation Service The expansion will add biological buffer manufacturing to the site's established chemistry capabilities, providing customers in research, diagnostics, biotechnology, and biopharmaceutical manufacturing with an integrated offering. By supporting customers from research and development through scale-up, commercial production, the expanded facility will help advance India's strategic role in global life science innovation. The facility reserves 34% of its site area for greenbelt, including trees and vegetation that help support environmental protection and sustainable operations. The Jigani site will manufacture biological buffers and raw materials for diagnostic applications used in DNA research, cell culture, diagnostics, and drug manufacturing. These materials will be produced locally under temperature-controlled conditions. This will help to improve supply reliability, reduce import dependence, and enable faster responses to customer's scientific and manufacturing needs, as well as reinforces Merck's in-region, for-region approach to strengthening supply and access across key markets. "Merck's Bengaluru manufacturing Hub shows what the India-Germany partnership can achieve when world-class German enterprise meets India's manufacturing ambition. In the year we celebrate 75 years of diplomatic relations, Merck will make advanced materials in Bengaluru for pharmaceutical research and semiconductor manufacturing, for India and for the world, in the true spirit of Make in India," said Shri Amardeep Singh Bhatia, IAS, Secretary to the Government of India, Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry. "With its expansion plans of Jigani Bangalore site, Merck is taking its Life Science presence in India by scaling up its advanced materials production capabilities to enable and amplify pharmaceutical research and semiconductor manufacturing ecosystems. The initiative supports bilateral research and economic prosperity in pharma, biotech and advanced manufacturing, an exemplary development with regard to Indo German high-tech cooperation in a strategic sector," said Alexandre Callegaro, Minister Counsellor, Head of the Department for Economic and Global Affairs, German Embassy, New Delhi. Operational since 2003, the 10 acres Jigani site has established capabilities in specialty and fine chemicals, custom synthesis, and catalog product manufacturing. The site also includes a Microbiology Application and Training Lab, a state-of-art Stable Isotopes Manufacturing Plant established through collaboration with the Heavy Water Board under the Department of Atomic Energy, Government of India, and a 7,200 square meter distribution center with temperature-controlled infrastructure.

Life sciences firms push into digital tools, ADCs and biocomputing. Digital capability is becoming a sharper priority in life sciences as biopharma growth increases pressure on complex supply chains. 86% of biopharma leaders are planning to invest in digital agility, reflecting expectations that more mature technology systems could improve logistics and support faster industry development. Moderna and Merck & Co received European Medicines Agency PRIME designation for their personalised melanoma vaccine, mRNA-4157/V940, in combination with Keytruda. Tubulis also entered a strategic licence agreement with Bristol Myers Squibb to advance antibody-drug conjugates. On April 20th, the companies announced a potential deal value of over $1 billion, including an upfront payment of $22.75 million. Biocomputing is drawing attention through organoid intelligence, a proposed biological computer powered by millions of human brain cells, while organoids are already used in biomedical research to detect drug toxicity, analyse organ development and support personalised treatment. AI remains a central ethical concern after Geoffrey Hinton left Google warning, "No one will know what's true anymore," even as life sciences applications include disease detection systems and AI-enabled prosthetics. Originally reported by biotalent.com Read the source